Jaipur-based healthtech startup Aignosis has raised ₹40 million in a Seed funding round to scale its artificial intelligence-powered screening platform for autism and developmental concerns. The round was led by Antler and Nikhil Kamath, with participation from angel investors Varun Dua and IIMA Ventures. The company will use the fresh capital to expand early screening access across India's public and private healthcare networks.
Funding and Strategic Priorities
The funding follows an initial round in 2024 supported by Rajneesh Bhandari and Amit Jain. Cofounders Raksheet Jain and Divyansh Mangal described the new capital as a shift from technology validation to large-scale healthcare deployment. The startup aims to make autism screening more accessible, strengthen referral pathways, and build a model that works across government and private care settings.
Regulatory Progress and Technology
Aignosis has completed its Central Drugs Standard Control Organisation regulatory process and received Class B certification for its screening technology. The startup was selected for the Google for Startups Accelerator: AI First 2025 cohort and was incubated at IIMA Ventures. Its system is designed for children aged 16 months to nine years and acts as an initial screening layer rather than a diagnostic tool.
How the Screening Works
The platform uses a standard laptop and webcam to capture a short video organized around nine stimulus modules. Computer vision then analyzes behavioral signals including gaze, response to name, and reactions to facial expressions. The resulting risk report indicates whether a child may need formal clinical assessment, but it is not intended to provide a diagnosis.
Deployment Model and Partnerships
Aignosis operates through a Clinic-in-Clinic model that enables pediatricians to incorporate developmental screening into their existing practices. It has deployed its system across more than 20 government Primary Health Centers in Rajasthan and has partnered with Mankind Pharma, whose nearly 1,300 medical representatives support screening camps across India. The company is also starting operations with Apollo Shines, the Apollo Group's school infirmary division, across around 125 schools.
Early Traction and Investor Confidence
The startup has completed more than 8,000 screenings so far and says its technology has been evaluated against established clinical assessments and expert judgment. Investor Nikhil Kamath said most healthcare innovation in India remains at the top of the pyramid, while Aignosis is starting in government health centers and small clinics instead of metropolitan private hospitals. He described the approach as distribution thinking that can move the needle at scale.
Expansion Roadmap
Aignosis is targeting at least 100,000 screenings by the end of FY27, using its Rajasthan experience as a reference for wider government adoption. The company plans to expand into Punjab, the National Capital Region, Haryana, Tamil Nadu, Jharkhand, Karnataka, and Maharashtra. Its focus is on building screening and referral access across both government and private healthcare networks.
With new Seed funding and regulatory validation in place, Aignosis is positioned to broaden early developmental screening beyond urban specialty centers. Its distribution-first approach targets government health centers, small clinics, and school-based programs, addressing a clear gap in pediatric care. Continued success will depend on sustained partnerships, effective referral coordination, and the ability to integrate screening into routine care across multiple states.